Talon Resources Targets Ontario Gold Growth After AIM Move and Eagle Lake Acquisition, CEO Says. Watch here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksDEST.L Regulatory News (DEST)

  • There is currently no data for DEST

Holding(s) in Company

19 Sep 2017 17:00

RNS Number : 2064R
Destiny Pharma PLC
19 September 2017
 

TR-1: Standard form for notification of major holdings

 

NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible)i

1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attachedii:

Destiny Pharma Plc

 

1b. Please indicate if the issuer is a non-UK issuer (please mark with an "X" if appropriate)

Non-UK issuer

2. Reason for the notification (please mark the appropriate box or boxes with an "X")

An acquisition or disposal of voting rights

X

An acquisition or disposal of financial instruments

An event changing the breakdown of voting rights

Other (please specify)iii:

3. Details of person subject to the notification obligationiv

Name

CANACCORD GENUITY GROUP INC

City and country of registered office (if applicable)

VANCOUVER, CANADA

4. Full name of shareholder(s) (if different from 3.)v

Name

DISCRETIONARY CLIENTS

City and country of registered office (if applicable)

5. Date on which the threshold was crossed or reachedvi:

18 SEPTEMBER 2017

6. Date on which issuer notified (DD/MM/YYYY):

19 SEPTEMBER 2017

7. Total positions of person(s) subject to the notification obligation

% of voting rights attached to shares (total of 8. A)

% of voting rights through financial instruments(total of 8.B 1 + 8.B 2)

Total of both in % (8.A + 8.B)

Total number of voting rights of issuervii

Resulting situation on the date on which threshold was crossed or reached

11.5891%

0.00

11.5891%

 

41,651,770

 

Position of previous notification (if

applicable)

N/A

N/A

N/A

 

8. Notified details of the resulting situation on the date on which the threshold was crossed or reachedviii

A: Voting rights attached to shares

Class/type ofshares

ISIN code (if possible)

Number of voting rightsix

% of voting rights

Direct

(Art 9 of Directive 2004/109/EC) (DTR5.1)

Indirect

(Art 10 of Directive 2004/109/EC) (DTR5.2.1)

Direct

(Art 9 of Directive 2004/109/EC) (DTR5.1)

Indirect

(Art 10 of Directive 2004/109/EC) (DTR5.2.1)

GB00BDHSP575

N/A

4,827,070

N/A

11.5891%

SUBTOTAL 8. A

4,827,070

11.5891%

 

 

B 1: Financial Instruments according to Art. 13(1)(a) of Directive 2004/109/EC (DTR5.3.1.1 (a))

Type of financial instrument

Expirationdatex

Exercise/Conversion Periodxi

Number of voting rights that may be acquired if the instrument is

exercised/converted.

% of voting rights

SUBTOTAL 8. B 1

 

 

B 2: Financial Instruments with similar economic effect according to Art. 13(1)(b) of Directive 2004/109/EC (DTR5.3.1.1 (b))

Type of financial instrument

Expirationdatex

Exercise/Conversion Period xi

Physical or cash

settlementxii

Number of voting rights

% of voting rights

SUBTOTAL 8.B.2

 

 

 

 

9. Information in relation to the person subject to the notification obligation (please mark the

applicable box with an "X")

Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuerxiii

Full chain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held starting with the ultimate controlling natural person or legal entityxiv (please add additional rows as necessary)

X

Namexv

% of voting rights if it equals or is higher than the notifiable threshold

% of voting rights through financial instruments if it equals or is higher than the notifiable threshold

Total of both if it equals or is higher than the notifiable threshold

Canaccord Genuity Group Inc.

11.5891%

11.5891%

Canaccord Genuity Wealth Group Holdings Limited

11.5891%

11.5891%

Canaccord Genuity Wealth Group Holdings (Jersey) Limited

11.5891%

11.5891%

Hargreave Hale Limited

11.5891%

11.5891%

[1] Each company set out in this table is ultimately owned by Canaccord Genuity Group Inc.

 

10. In case of proxy voting, please identify:

Name of the proxy holder

The number and % of voting rights held

The date until which the voting rights will be held

11. Additional informationxvi

This disclosable event is as a result of the acquisition of Hargreave Hale Limited by Canaccord Genuity Group Inc., through its wholly-owned subsidiary Canaccord Genuity Wealth Group Holdings (Jersey) Limited.

 

 

 

Place of completion

London

Date of completion

19/09/17

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
HOLEASNNFLPXEFF
Date   Source Headline
13th Aug 20247:00 amRNSCancellation - Destiny Pharma plc
12th Aug 20247:00 amRNSLast Day of Dealings on AIM
5th Aug 202411:58 amRNSDirector/PDMR Shareholding
31st Jul 202411:00 amRNSResult of GM and Cancellation of Trading on AIM
15th Jul 20247:00 amRNSProposed Cancellation of Admission to Trading
20th Jun 20247:00 amRNSExercise of Options and Total Voting Rights
18th Jun 20247:00 amRNSEfficacy of XF-70 in Fungal Skin Infections
12th Jun 202412:16 pmRNSResult of Annual General Meeting
12th Jun 202411:00 amRNS2024 Annual General Meeting and Statement
11th Jun 20247:00 amRNSDestiny Pharma's XF-73 Nasal Awarded MHRA ILAP
24th May 20247:00 amRNSExercise of Options and Total Voting Rights
9th May 20242:35 pmRNSPosting of Annual Report and Notice of AGM
25th Apr 20247:00 amRNSFull year results and review of strategic options
8th Apr 20247:00 amRNSNotice of Full Year Results
19th Mar 20242:47 pmRNSExercise of Options and Total Voting Rights
31st Jan 20247:00 amRNSClinical development update
22nd Jan 20247:00 amRNSAppointment of Nominated Adviser and Sole Broker
4th Jan 20247:00 amRNSYear End Business Update
20th Oct 20237:00 amRNSGrant of Share Options
19th Oct 20237:00 amRNSDirector/PDMR Shareholding
17th Oct 20237:01 amRNSXF Pipeline Update Meeting
17th Oct 20237:00 amRNSPublication of new microbiological data for XF-73
10th Oct 20237:00 amRNSDirector/PDMR Shareholding
4th Oct 202312:34 pmRNSDirector/PDMR Shareholding
27th Sep 20237:00 amRNSNotice of XF Pipeline Update Meeting
20th Sep 20237:00 amRNSInterim Results
23rd Aug 20237:00 amRNSNotice of Interim Results
31st Jul 202312:01 pmRNSPublication of new data for XF-73
25th Jul 20237:00 amRNSAppointment of new Chairman
19th Jul 202312:55 pmRNSBoard changes including appointment of new CEO
7th Jul 20237:00 amRNSExercise of Options and Total Voting Rights
6th Jul 20237:00 amRNSPositive findings from recent SAB meeting
29th Jun 20237:00 amRNSBusiness Update
26th May 20233:27 pmRNSDirector/PDMR Shareholding
26th May 20237:00 amRNSDirector Dealing
25th May 202312:23 pmRNSResult of Annual General Meeting
25th May 20237:00 amRNSDr Debra Barker Appointed Interim CEO
12th May 202312:24 pmRNSGrant of Share Options
2nd May 20237:00 amRNSPositive results from SPOR-COV® research
26th Apr 20234:10 pmRNSPosting of Annual Report and Notice of AGM
26th Apr 202310:05 amRNSExercise of Options and Total Voting Rights
13th Apr 20237:00 amRNSAudited results for year ended 31 December 2022
4th Apr 20237:00 amRNSLandmark data published on NTCD-M3
3rd Apr 20237:00 amRNSNotice of Results and Investor Presentation
24th Mar 20237:00 amRNSLandmark XF-73 Phase 2 data published in journal
16th Mar 20233:29 pmRNSResult of General Meeting and Total Voting Rights
15th Mar 20234:02 pmRNSResult of Open Offer
6th Mar 202310:50 amRNSExercise of Options and Total Voting Rights
6th Mar 202310:31 amRNSHolding(s) in Company
28th Feb 20233:55 pmRNSPosting of Circular and Notice of General Meeting

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.